Mylan announced the launch of Ibandronate Sodium Injection, the generic version of Roche’s Boniva Injection. Boniva is indicated for the treatment of osteoporosis in postmenopausal women.
Boniva is a bisphosphonate that inhibits osteoclast activity and reduces bone resorption and turnover. Its action on bone is based on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
RELATED: Osteoporosis Treatments
Ibandronate Sodium Injection is available as a 1mg (base)/mL strength, in 3mL prefilled glass syringes.
For more information call (800) RX-MYLAN or visit Mylan.com.